Cardiac troponin I measurement with the ACCESS® immunoassay system:: analytical and clinical performance characteristics

被引:0
|
作者
Christenson, RH
Apple, FS
Morgan, DL
Alonsozana, GL
Mascotti, K
Olson, M
McCormack, RT
Wians, FH
Keffer, JH
Duh, SH
机构
[1] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA
[2] Univ Maryland, Sch Med, Dept Med & Res Technol, Baltimore, MD 21201 USA
[3] Hennepin Cty Med Ctr, Dept Lab Med & Pathol, Minneapolis, MN 55415 USA
[4] Univ Texas, SW Med Ctr, Dallas, TX 75235 USA
[5] Beckman Instruments Inc, Chaska, MN 55318 USA
关键词
D O I
暂无
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
We evaluated the ACCESS(R) cardiac troponin I (cTnI) immunoassay as a marker for myocardial infarction (MI). Total imprecision was 6.0% to 13.5%, the minimum detectable concentration was 0.007 mu g/L, and the limit of quantitation was 0.046 mu g/L. Comparison of cTnI measurement between the ACCESS and Stratus systems (n = 114) showed a proportional difference: ACCESS cTnI = 0.0996 Stratus cTnI + 0.049 mu g/L (r = 0.811). Fifty-nine of 61 ambulatory patients without cardiac symptoms had no detectable cTnI (95% range, 0.00 to 0.025 mu g/L). The optimum cutoff for discriminating MI (n = 289, 45 with MI) was 0.15 mu g/L by receiver operator characteristic curve analysis; at this cutoff, the ACCESS cTnI assay showed a sensitivity of 88.9% (95% CI, 79.7-98.1%) and specificity of 91.8% (95% CI, 88.4-95.2%). The ACCESS cTnI assay results showed 89.4% and 93.0% concordance with the MB isoenzyme of creatine kinase (CK-MB) mass and Stratus cTnI results, respectively, for classification of patients with suspected MI. The ACCESS cTnI assay appears to show sensitivity and specificity comparable with those of both CK-MB mass and Stratus cTnI assays for the diagnosis of MI in patients presenting within 12 h of onset of symptoms.
引用
收藏
页码:52 / 60
页数:9
相关论文
共 50 条
  • [21] Ultrasensitive Cross-species Measurement of Cardiac Troponin-I Using the Erenna Immunoassay System
    Schultze, A. Eric
    Konrad, Robert J.
    Credille, Kelly M.
    Lu, Quynh Anh
    Todd, John
    TOXICOLOGIC PATHOLOGY, 2008, 36 (06) : 777 - 782
  • [22] Analytical and clinical performance of the PATHFAST® troponin I assay
    Okamura, Y.
    Watanabe, H.
    Nema, T.
    Hiruta, N.
    Yokoi, H.
    CLINICAL CHEMISTRY, 2008, 54 (06) : A78 - A79
  • [23] Clinical and analytical standardization issues confronting cardiac troponin I
    Apple, FS
    CLINICAL CHEMISTRY, 1999, 45 (01) : 18 - 20
  • [24] ANALYTICAL PERFORMANCE OF THE STRATUS(R) CARDIAC TROPONIN-I
    MOORE, JJ
    GEYER, SJ
    SAX, SM
    CLINICAL CHEMISTRY, 1995, 41 (06) : S57 - S57
  • [25] Performance characteristics of five cardiac Troponin I assays
    La'ulu, Sonia L.
    Roberts, William L.
    CLINICA CHIMICA ACTA, 2010, 411 (15-16) : 1095 - 1101
  • [26] Evaluation of Kryptor cardiac troponin I immunoassay
    Lefèvre, G
    Graïne, H
    Bakkouch, K
    Garbarz, E
    Marlin, G
    Michel, PL
    Capeau, J
    ANNALS OF CLINICAL BIOCHEMISTRY, 2002, 39 : 145 - 147
  • [27] Clinical evaluation of cardiac troponin I (cTnI) measurement using the Stratus CS and Immulite immunoassay systems.
    Gaze, DC
    Collinson, PO
    CLINICAL CHEMISTRY, 2001, 47 (06) : A201 - A201
  • [28] Analytical and clinical performance evaluation of a new high-sensitivity cardiac troponin I assay
    Yang, Shuo
    Zhang, Qian
    Yang, Boxin
    Li, Zijing
    Sun, Wenyuan
    Cui, Liyan
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2022, 60 (08) : 1299 - 1307
  • [29] Analytical and clinical comparison of the Ortho-Clinical Diagnostic Vitros and Beckman Access Cardiac Troponin I assays.
    Quist, HE
    Otto, AP
    Doyle, PJ
    Murakami, MM
    Apple, FS
    CLINICAL CHEMISTRY, 2003, 49 (06) : A62 - A62
  • [30] Cardiac Troponin Assay Classification by Both Clinical and Analytical Performance Characteristics: A Study on Outcome Prediction
    Venge, Per
    Lindahl, Bertil
    CLINICAL CHEMISTRY, 2013, 59 (06) : 976 - 981